Copegus

Manufactured by Roche

Sourced in Switzerland

Copegus is a laboratory equipment product manufactured by Roche. It is a technical device used for research and analysis in laboratory settings.

Automatically generated - may contain errors

Lab products found in correlation

Pegasys, by Roche (9 mentions) Sovaldi, by Gilead Sciences (2 mentions) Pegintron, by Merck Group (1 mentions) Rebetol, by Merck Group (1 mentions) Peg ifn α2b, by Merck & Co (1 mentions) Rebetol, by Merck & Co (1 mentions) Pegifnα 2a, by Roche (1 mentions)

12 protocols using copegus

Hepatitis C Treatment Regimen after Liver Transplant

Check if the same lab product or an alternative is used in the 5 most similar protocols

The overall antiviral treatment duration was scheduled as 12 weeks of TVR/PegIFN/RBV triple therapy and 36 weeks of consecutive PegIFN/RBV dual therapy. Primary immunosuppression was switched from tacrolimus (TAC, Prograf®) to cyclosporine (CyA, Sandimmun Optoral®) prior to the beginning of treatment, and a sufficient therapeutic range for the CyA dosage was defined as a total body clearance (TBC) from 80 to 120 ng/mL depending on the time that had elapsed since OLT. In addition, all patients underwent a lead-in phase of 4 weeks of RBV (Copegus©; Roche) at a daily dose of 600 mg to estimate hematological and renal tolerance. Hemoglobin and serum creatinine levels were measured once a week during the lead-in phase, and the RBV dosage was eventually adjusted. Triple therapy was then begun with TVR (Incivo©; Janssen-Cilag International NV), PegIFN (Pegasys©; Roche), and RBV (Copegus©; Roche). TVR was given at either two daily doses of 1,125 mg or three daily doses of 750 mg, respectively, to reach a daily dose of 2,250 mg. The CyA dosage was reduced by 50% for each patient on the day that TVR treatment started.

Klein F., Neuhaus R., Eurich D., Hofmann J., Bayraktar S., Pratschke J, & Bahra M. (2016). Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepatitis Research and Treatment, 2016, 8325467.

+ Open protocol

+ Expand

Peginterferon, Ribavirin, and Pioglitazone for HCV

Check if the same lab product or an alternative is used in the 5 most similar protocols

All subjects received at least 24 weeks of PIO 30 mg/day prior to PegIFN/RBV. Management for hepatotoxicity was prespecified based on elevations in transaminases, bilirubin, or signs of hepatic decompensation. PegIFN alfa-2a (Pegasys™; Roche (Genentech)) was dosed at 180 mcg/week. Ribavirin (Copegus™; Roche(Genentech)) dose was weight-based, with doses of 1000(<75 kg) or 1200mg/day(≥75 kg) divided twice daily. PegIFN and RBV doses were reduced if prespecified toxicity criteria were met. Dose escalation was permitted if toxicities resolved. Concurrent use of growth factors was permitted for neutropenia and anemia. Stopping rules for treatment futility were applied including <2 log₁₀ drop in HCV RNA after 12 weeks or detectable HCV RNA after 24 weeks of PegIFN/RBV/PIO.

Marks K., Kitch D., Chung R.T., Hadigan C., Andersen J., Tien P., Luetkemeyer A., Alston-Smith B, & Glesby M.J. (2014). Pilot Study of Pioglitazone Prior to HCV Re-treatment in HIV/HCV Genotype 1-Infected Subjects with Insulin Resistance and Prior Nonresponse to Peginterferon and Ribavirin Therapy: A5239. Journal of acquired immune deficiency syndromes (1999), 65(3), 345-349.

+ Open protocol

+ Expand

Peginterferon and Ribavirin for Chronic Hepatitis C in Hemophilia

Check if the same lab product or an alternative is used in the 5 most similar protocols

This study was designed as a single-center open-label one-arm observational study of peginterferon α-2a (Pegasys, Roche, Basel, Switzerland) and ribavirin (Copegus, Roche) combination therapy of CHC infection in hemophilia A. The duration on enrollment was 22 months, from March 2007 to December 2008. Eligible patients received 180 µg of peginterferon α-2a subcutaneously once a week in combination with 800-1,200 mg of oral ribavirin per day, according to their genotype and body weight. Patients with virus genotypes 1 or 6 with a weight below 75 kg were given 1,000 mg of oral ribavirin per day, while patients over 75 kg received 1,200 mg of oral ribavirin daily. Patients with virus genotypes 2 or 3 were given a constant ribavirin dose of 800 mg/day. The treatment duration for genotype 1 or 6 infections was 48 weeks, and 24 weeks for patients with genotypes 2 or 3.9

Yang S.Y., Lee H.W., Lee Y.J., Park S.J., Yoo K.Y, & Kim H.J. (2015). Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. Clinical and Molecular Hepatology, 21(2), 125-130.

+ Open protocol

+ Expand

Pegylated Interferon and Ribavirin Therapy for HCV in Diverse Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

The VIRAHEP-C study is a multicenter study of pegIFN/RBV therapy in African-American and Caucasian patients with HCV genotype 1 infection ^{6 (link)}. Only patients that classified themselves by ethnicity as either African-American or Caucasian American were included. Patients also needed to be aged between 18 and 70 years, be treatment naïve, and have detectable HCV RNA and histologic evidence of chronic HCV. The study enrolled 401 patients from eight clinical centers in the United States and pegIFN/RBV therapy started between July 2002 and December 2003. Patients were treated with 180μg pegylated interferon α-2a (Pegasys, Roche Pharmaceuticals, Nutley, NJ) per week and 1000–1200 mg RBV (Copegus, Roche Pharmaceuticals, Nutley, NJ) per day for up to 48 weeks. All participants provided written informed consent, including consent for genetic testing.

Johansson S., Talloen W., Tuefferd M., Darling J.M., Scholliers A., Fanning G., Fried M.W, & Aerssens J. (2015). Plasma levels of growth-related oncogene (CXCL1-3) associate with fibrosis and platelet counts in HCV-infected patients. Alimentary pharmacology & therapeutics, 42(9), 1111-1121.

+ Open protocol

+ Expand

Vδ2 T cells in Chronic HCV Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Data reported in this study were obtained from 43 patients with chronic HCV infection, and 39 healthy age- and sex-matched volunteers as described in Supplementary Table S1. Patients were excluded if they were coinfected with HIV or other hepatitis viruses or had received antiviral or immunomodulatory HCV treatment before blood sampling. 7 chronic HCV-infected patients given an anti-viral combination treatment of pegylated interferon (Peg-IFN)-α (180μg/week, Pegasys; Roche) and Ribavirin (RBV) (1g/day, Copegus; Roche) were also enrolled. The study protocol was approved by the ethical committee of the Second Affiliated Hospital of Chongqing Medical University, and written informed consent was obtained from all participants. The methods were carried out in accordance with the approved guidelines.
Peripheral blood mononuclear cells (PBMCs) were isolated from all enrolled subjects by Ficoll-Isopaque (TBDscience, China) gradient centrifugation. Paired analysis of liver and blood Vδ2 T cells was performed for 8 patients. Except for the pathological evaluation, liver biopsy specimens were homogenized for the isolation of liver-infiltrating lymphocytes (LILs). The basic clinical data for the HCV-infected subjects with available liver biopsy samples are presented in Supplementary Table S2.

Yin W., Tong S., Zhang Q., shao J., Liu Q., Peng H., Hu H., Peng M., Hu P., Ren H., Tian Z, & Zhang D. (2016). Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Scientific Reports, 6, 26296.

+ Open protocol

+ Expand

HCV Genotype-Guided Treatment with SOF-based Regimens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients infected with HCV genotype (GT) 3, regardless of underlying cirrhosis, were treated with sofosbuvir (SOF; MyHep®, Mylan Laboratories Limited) plus pegylated interferon (Peg-IFN; Pegasys®, Roche Pharmaceuticals, or PegIntron®, Merck Sharp & Dohme Corp.), weight-based ribavirin (RBV; Copegus®, Roche Pharmaceuticals, or Rebetol®, Merck Sharp & Dohme Corp.), and triple-drug therapy (SOF + Peg-IFN + RBV) for 12 weeks.
Patients infected with HCV GT1, GT2, GT4, or GT6 without cirrhosis were treated with a fixed-dose combination of SOF + Ledipasvir (SOF + LDV) in a single tablet (Ledvir®, Mylan Laboratories Limited) for 12 weeks, whereas those with cirrhosis were treated with SOF + LDV plus weight-based RBV (SOF + LDV + RBV) for 12 weeks.

Sirinawasatien A, & Supawan P. (2024). Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment. Medicine, 103(19), e38096.

+ Open protocol

+ Expand

Sofosbuvir and Ribavirin with/without Peginterferon for Hepatitis C

Check if the same lab product or an alternative is used in the 5 most similar protocols

This is a prospective, interventional, single arm, open label study conducted at a major tertiary care hospital with large liver transplant program. Patients were enrolled in the study from January 2014 through March 2015. The study was approved by the local Institutional Review Board (IRB) (RAC#2141038). Informed consents were obtained from all patients.
Patients received sofosbuvir (Sovaldi®, Gilead Sciences Inc.) and ribavirin (Copegus®, Hoffmann-La Roche Ltd.), with or without pegylated interferon alfa-2a (Pegasys®, Hoffmann-La Roche Ltd.), for either 12 or 24 weeks.

Ajlan A., Al-Jedai A., Elsiesy H., Alkortas D., Al-Hamoudi W., Alarieh R., Al-Sebayel M., Broering D, & Aba Alkhail F. (2016). Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients. Canadian Journal of Gastroenterology & Hepatology, 2016, 2872371.

+ Open protocol

+ Expand

Sofosbuvir and Ribavirin with Pegylated Interferon for Hepatitis C Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

The patients were treated with one tablet of 400 mg SOF (Sovaldi, Gilead Sciences, Inc., USA) and oral tablets of RBV (Copegus, Roche, Europe) based on body weight: < 75 kg, 1000 mg; < 75 kg, 1200 mg and modified according to patient tolerability, plus 180 μg PegINFα-2 (Pegasys, Roche, Europe) given via subcutaneous injection once weekly. The endpoint was SVR12 defined as HCV RNA < 15 IU/ml undetectable at the actual end of treatment (EOT) of 12 weeks and HCV RNA undetectable 12 weeks after planned EOT. Viral relapse was HCV RNA undetectable at EOT, but detectable HCV RNA > 15 IU/ml levels 12 weeks after planned EOT. Data were collected at three time points: (1) baseline (before initiating therapy); (2) at end of treatment (EOT) (12 weeks) and (3) 12 weeks after the treatment cessation (SVR12) (Figure 1).

Abdel-Moneim A., Abood A., Abdel-Gabaar M., Zanaty M.I, & Ramadan M. (2018). Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients. Clinical and Experimental Hepatology, 4(3), 191-196.

+ Open protocol

+ Expand

Combination Therapy for Chronic HCV Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

The patients were treated with standard combination therapy using pegylated IFNa-2a (Peg-IFNa-2a; Pegasys, Roche, Basel, Switzerland), 180 µg per week, in combination with ribavirin (RBV) (Copegus, Roche), 1,000 - 1,200 mg per day. HCV infected patients with genotypes 1 and 4 were treated for 48 weeks, whereas genotype 3-HCV positive patients were treated for 24 weeks according to standard methods for HCV therapy (26 (link)).

Afsharzadeh F., Bokharaei-Salim F., Esghaei M., Monavari S.H., Merat S., Poustchi H., Haj-Sheykholeslami A, & Keyvani H. (2016). The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection. Hepatitis Monthly, 16(12), e42388.

+ Open protocol

+ Expand

Hematological Decline in HCV Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

All of the patients were treated with combination of PEG-IFN-α-2a (Pegasys, Roche, Basel, Switzerland) and RBV (Copegus, Roche, Basel, Switzerland) or PEG-IFN-α-2b (Pegintron, Schering-plough, Puerto Rico, USA) and RBV (Rebetol, Schering-plough, Puerto Rico, USA). The dose of Pegasys was 180 μg subcutaneously once a week in combination with oral RBV 800 – 1,200 mg per day according to patients’ weight. The dose of Pegintron was 80, 100 or 120 μg subcutaneously once a week according to patients’ weight in combination with oral RBV 800-1,200 mg per day according to patients’ weight.
The decline of hematological components at week 4 of therapy was chosen as the clinical endpoint. Several cut-off values were assessed for each blood component and the best cut-off value according to the lower P value for each parameter was taken.

Pouryasin M., Keshvari M., Sharafi H., Alavian S.M., Behnava B., Alavian S.E, & Pouryasin A. (2016). The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Hepatitis Monthly, 16(2), e35278.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!